Brighton and Sussex Medical School

Low-Dose Interleukin-2 Shows Promise in Slowing Motor Neurone Disease Progression in Landmark MIROCALS Trial

- The MIROCALS clinical trial demonstrated that low-dose interleukin-2 (IL2LD) is safe and reduced the risk of death by over 40% in approximately 80% of motor neurone disease patients with lower levels of a specific biomarker. - The groundbreaking study provides compelling evidence that modifying the immune system could be an effective strategy for altering MND/ALS progression, potentially adding to the disease-modifying effects of riluzole. - While not yet licensed for MND treatment, IL2LD increases regulatory T cells to reduce inflammation, and ILTOO Pharma has secured exclusive licensing rights to pursue regulatory approval for this novel therapeutic approach.